QA / RA signal reading
How to read FDA warning letters for upstream quality-system signals
Warning letters become more useful when teams classify the control signal behind the subject line.
Articles
Short articles based on public FDA source documents. Each article links to the warning letters it discusses.
FDA Warning Monitor turns public FDA warning letters, recall items, and enforcement-source pages into practical reads on what changed, which pattern it fits, and what quality, regulatory, supplier-risk, or claims-review teams may want to check next.
QA / RA signal reading
Warning letters become more useful when teams classify the control signal behind the subject line.
Online seller enforcement
Cluster days matter because they show where website claims, ecommerce routes, and product positioning are drawing FDA attention.
Marketplace monitoring
FDA's June 17, 2026 Amazon warning letter is a fresh reminder that marketplace listings can become source evidence.
Telehealth claims
Public patient-facing pages, condition copy, and treatment funnels can become reviewable claims evidence.
OTC drug quality
Supplier documentation is not a substitute for a quality system that proves the result is reliable.
Sterile drug manufacturing
Repeated media-fill failures, ISO 5 airflow gaps, and weak stability testing made the Sato warning letter more than a routine drug CGMP item.
GLP-1 API traceability
FDA's Harbin Jixianglong Biotech warning letter turns one GLP-1 supply-chain question into a practical records check: who made it?
Supplements
Disease claims, blog posts, social links, and intended use issues in a recent dietary supplement warning letter.
Online claims
How FDA reviewers used public web pages, social media, and online purchase paths in recent letters.
Digest
Recent warning letters, Class I recall entries, and source-health notes from the May 13 monitor run.